Do analysts rate NXL or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXL or PETV more profitable?

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -3,018.12% -191.88% -166.43% PetVivo -902.82% -4,813.07% -281.78%

Does the media prefer NXL or PETV?

In the previous week, PetVivo had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 5 mentions for PetVivo and 4 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.99 beat PetVivo's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PetVivo 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NXL or PSTV?

Plus Therapeutics has a consensus price target of $56.40, suggesting a potential upside of 1,214.69%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Does the media prefer NXL or PSTV?

In the previous week, Nexalin Technology and Nexalin Technology both had 4 articles in the media. Nexalin Technology's average media sentiment score of 0.99 beat Plus Therapeutics' score of 0.97 indicating that Nexalin Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLSS or NXL?

In the previous week, Nexalin Technology had 3 more articles in the media than Milestone Scientific. MarketBeat recorded 4 mentions for Nexalin Technology and 1 mentions for Milestone Scientific. Nexalin Technology's average media sentiment score of 0.99 beat Milestone Scientific's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CTSO or NXL?

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,308.17%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Nexalin Technology (NXL) Competitors

$0.34 -0.01 (-3.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 +0.00 (+0.96%)

As of 07:31 PM Eastern

Compare

NXL vs. PETV, NMTC, PSTV, MLSS, and CTSO

Should you buy Nexalin Technology stock or one of its competitors? MarketBeat compares Nexalin Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nexalin Technology include PetVivo (PETV), NeuroOne Medical Technologies (NMTC), Plus Therapeutics (PSTV), Milestone Scientific (MLSS), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Nexalin Technology compare to PetVivo?

Nexalin Technology (NASDAQ:NXL) and PetVivo (NASDAQ:PETV) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
PetVivo	-902.82%	-4,813.07%	-281.78%

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nexalin Technology has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	23.51	-$8.22M	-$0.47	N/A
PetVivo	$1.05M	30.64	-$10.95M	-$0.38	N/A

In the previous week, PetVivo had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 5 mentions for PetVivo and 4 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.99 beat PetVivo's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PetVivo	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nexalin Technology has a beta of 3.79, indicating that its share price is 279% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

Nexalin Technology beats PetVivo on 8 of the 14 factors compared between the two stocks.

How does Nexalin Technology compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

NeuroOne Medical Technologies has higher revenue and earnings than Nexalin Technology. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.40	-$3.61M	-$0.85	N/A
Nexalin Technology	$300K	23.51	-$8.22M	-$0.47	N/A

In the previous week, Nexalin Technology had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 4 mentions for Nexalin Technology and 3 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Nexalin Technology's score of 0.99 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 25.3% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Nexalin Technology's net margin of -3,018.12%. NeuroOne Medical Technologies' return on equity of -99.43% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

NeuroOne Medical Technologies presently has a consensus target price of $11.67, indicating a potential upside of 249.30%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.79, indicating that its share price is 279% more volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Nexalin Technology on 10 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to Plus Therapeutics?

Nexalin Technology (NASDAQ:NXL) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Nexalin Technology has a beta of 3.79, meaning that its stock price is 279% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Plus Therapeutics has a net margin of -230.24% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Nexalin Technology has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	23.51	-$8.22M	-$0.47	N/A
Plus Therapeutics	$5.21M	5.67	-$22.39M	-$2.30	N/A

Plus Therapeutics has a consensus price target of $56.40, suggesting a potential upside of 1,214.69%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Nexalin Technology and Nexalin Technology both had 4 articles in the media. Nexalin Technology's average media sentiment score of 0.99 beat Plus Therapeutics' score of 0.97 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nexalin Technology beats Plus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, Nexalin Technology had 3 more articles in the media than Milestone Scientific. MarketBeat recorded 4 mentions for Nexalin Technology and 1 mentions for Milestone Scientific. Nexalin Technology's average media sentiment score of 0.99 beat Milestone Scientific's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Scientific has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.79, meaning that its stock price is 279% more volatile than the broader market.

Milestone Scientific has higher revenue and earnings than Nexalin Technology. Milestone Scientific is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.18	-$6.93M	-$0.05	N/A
Nexalin Technology	$300K	23.51	-$8.22M	-$0.47	N/A

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 12.5% of Milestone Scientific shares are owned by company insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Milestone Scientific has a net margin of -52.01% compared to Nexalin Technology's net margin of -3,018.12%. Milestone Scientific's return on equity of -60.26% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Milestone Scientific presently has a consensus price target of $1.00, indicating a potential upside of 212.21%. Given Milestone Scientific's stronger consensus rating and higher probable upside, equities research analysts plainly believe Milestone Scientific is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Milestone Scientific beats Nexalin Technology on 10 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Cytosorbents has higher revenue and earnings than Nexalin Technology. Cytosorbents is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.65	-$8.20M	-$0.19	N/A
Nexalin Technology	$300K	23.51	-$8.22M	-$0.47	N/A

In the previous week, Nexalin Technology had 3 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for Nexalin Technology and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Nexalin Technology's score of 0.99 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Nexalin Technology	Positive

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,308.17%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cytosorbents has a net margin of -31.85% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Cytosorbents has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.79, meaning that its share price is 279% more volatile than the broader market.

Summary

Cytosorbents beats Nexalin Technology on 10 of the 16 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$7.31M	$4.21B	$6.82B	$12.21B
Dividend Yield	N/A	2.11%	3.16%	6.23%
P/E Ratio	-0.73	40.97	28.68	24.36
Price / Sales	23.51	47.07	379.82	103.70
Price / Cash	N/A	36.90	23.06	36.93
Price / Book	1.71	4.47	5.76	6.49
Net Income	-$8.22M	$31.79M	$204.75M	$336.61M
7 Day Performance	-7.90%	-2.92%	0.45%	0.90%
1 Month Performance	-43.82%	-8.49%	-2.70%	-0.36%
1 Year Performance	-62.75%	18.84%	27.97%	31.26%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.9557 of 5 stars	$0.34 -3.5%	N/A	-61.4%	$7.31M	$300K	N/A	3	Short Interest Decrease Gap Down
PETV PetVivo	N/A	$0.83 +3.1%	N/A	+7.6%	$30.05M	$1.05M	N/A	20
NMTC NeuroOne Medical Technologies	2.817 of 5 stars	$3.35 +3.1%	$11.67 +248.3%	-18.1%	$28.28M	$12.10M	N/A	20	News Coverage Positive News
PSTV Plus Therapeutics	2.6704 of 5 stars	$4.08 +2.5%	$56.40 +1,282.4%	-46.7%	$27.40M	$5.21M	N/A	20
MLSS Milestone Scientific	1.2508 of 5 stars	$0.30 -9.7%	$1.00 +235.3%	-56.0%	$26.38M	$8.90M	N/A	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. PETV, NMTC, PSTV, MLSS, and CTSO

How does Nexalin Technology compare to PetVivo?

Summary

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Summary

How does Nexalin Technology compare to Plus Therapeutics?

Summary

How does Nexalin Technology compare to Milestone Scientific?

Summary

How does Nexalin Technology compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. PETV, NMTC, PSTV, MLSS, and CTSO

How does Nexalin Technology compare to PetVivo?

Do analysts rate NXL or PETV?

Is NXL or PETV more profitable?

Do institutionals and insiders hold more shares of NXL or PETV?

Which has higher valuation & earnings, NXL or PETV?

Does the media prefer NXL or PETV?

Which has more risk & volatility, NXL or PETV?

Summary

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Which has higher valuation & earnings, NMTC or NXL?

Does the media refer more to NMTC or NXL?

Do institutionals and insiders have more ownership in NMTC or NXL?

Is NMTC or NXL more profitable?

Do analysts prefer NMTC or NXL?

Which has more volatility & risk, NMTC or NXL?

Summary

How does Nexalin Technology compare to Plus Therapeutics?

Which has more volatility & risk, NXL or PSTV?

Do institutionals & insiders believe in NXL or PSTV?

Is NXL or PSTV more profitable?

Which has stronger valuation and earnings, NXL or PSTV?

Do analysts rate NXL or PSTV?

Does the media prefer NXL or PSTV?

Summary

How does Nexalin Technology compare to Milestone Scientific?

Does the media favor MLSS or NXL?

Which has more volatility & risk, MLSS or NXL?

Which has stronger valuation and earnings, MLSS or NXL?

Do insiders and institutionals believe in MLSS or NXL?

Is MLSS or NXL more profitable?

Do analysts prefer MLSS or NXL?

Summary

How does Nexalin Technology compare to Cytosorbents?

Which has higher earnings and valuation, CTSO or NXL?

Does the media favor CTSO or NXL?

Do analysts rate CTSO or NXL?

Do institutionals and insiders believe in CTSO or NXL?

Is CTSO or NXL more profitable?

Which has more risk & volatility, CTSO or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools